Danaher Co. (NYSE:DHR) Position Reduced by Marcum Wealth LLC

Marcum Wealth LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 3.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,196 shares of the conglomerate’s stock after selling 88 shares during the period. Marcum Wealth LLC’s holdings in Danaher were worth $548,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cape Investment Advisory Inc. bought a new stake in Danaher during the fourth quarter worth approximately $25,000. BKM Wealth Management LLC bought a new position in shares of Danaher in the fourth quarter valued at $27,000. Wetzel Investment Advisors Inc. bought a new position in shares of Danaher in the fourth quarter valued at $29,000. Rakuten Securities Inc. bought a new position in shares of Danaher in the fourth quarter valued at $36,000. Finally, Financial Connections Group Inc. bought a new position in shares of Danaher in the fourth quarter valued at $41,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 2.6 %

Danaher stock opened at $254.96 on Friday. The firm has a market cap of $188.85 billion, a price-to-earnings ratio of 43.21, a P/E/G ratio of 3.80 and a beta of 0.85. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $269.11. The firm has a fifty day moving average price of $254.46 and a two-hundred day moving average price of $245.26.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The business’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.36 EPS. As a group, analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Upgrades and Downgrades

DHR has been the topic of several research reports. StockNews.com raised Danaher from a “hold” rating to a “buy” rating in a report on Monday, June 17th. Citigroup lifted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Barclays lifted their price objective on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, TD Cowen boosted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $269.29.

Insider Activity

In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Matthew Mcgrew sold 46,377 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total transaction of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 148,783 shares of company stock valued at $37,536,717. Insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.